This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Pacira BioSciences's Median PS Value or its related term are showing as below:
PCRX'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.26 Med: 0.48 Max: 0.95
Current: 0.33
During the past 13 years, the highest Price to Median PS Value of Pacira BioSciences was 0.95. The lowest was 0.26. And the median was 0.48.
PCRX's Price-to-Median-PS-Value is ranked better than 89.98% of 499
companies
in the Drug Manufacturers industry
Industry Median: 0.85
vs PCRX: 0.33
Pacira BioSciences Median PS Value Historical Data
The historical data trend for Pacira BioSciences's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Pacira BioSciences's Median PS Value
For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacira BioSciences's Price-to-Median-PS-Value Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Pacira BioSciences's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 5.0495.
Pacira BioSciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $14.433.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacira BioSciences (NAS:PCRX) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Pacira BioSciences's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
24.05
/
72.88
=
0.33
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacira BioSciences Median PS Value Related Terms
Thank you for viewing the detailed overview of Pacira BioSciences's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PCRX has been successfully added to your 